Perrigo Recalls Tamper-Resistant PSE Product Due To Contamination
FDA on Dec. 21 identified the recall as class II, for violative products that may cause temporary or medically reversible adverse health consequences though the probability of serious consequences is remote. Perrigo acquired the Zephrex-D brand and rights to the formulation in 2016.
You may also be interested in...
US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.
Via Highland Pharmaceuticals agreement, Perrigo snaps up the only tamper-resistant pseudoephedrine formulation still available for licensing. It now goes up against Bayer – but will beat the pharma giant to market.
Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.